Erratum to ‘Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?’ [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796] (JTO Clinical and Research Reports (2025) 6(5), (S2666364325000128), (10.1016/j.jtocrr.2025.100796))

In the original published version of this article, the following errors were introduced during the copyediting process by the Suppliers. The text originally published “TCs and ACs are distinguished on the basis of mitotic count and the presence or absence of necrosis, whereas the Ki-67 index is not considered a criterion; the WHO acknowledges that it might be useful for the differential diagnosis between well - or poorly differentiated NENs.” Has been corrected to “Typical carcinoids and ACs are distinguished on the basis of mitotic count and presence or absence of necrosis; while Ki-67 index is not considered as a criteria, the WHO acknowledges that it might be useful for the differential diagnosis between well - or poorly - differentiated NENs.” The text originally published “Cooper et al. presented a case of a 61-year-old nonsmoker woman with a challenging diagnosis of AC with an aggressive evolution and progressive disease with concomitant chemoradiotherapy and somatostatin analogs in less than 12-month intervals.” Has been corrected to “Cooper and colleagues present here the case of a 61-year-old nonsmoker woman with a challenging diagnosis of AC with an aggressive evolution and progressive disease with concomitant chemoradiotherapy and somatostatin analogs in less than 12-month intervals". The text originally published “Control of tumor growth and functioning syndromes is the goal of advanced lung carcinoids, with the objective of improving patients’ quality of life and survival.” Has been corrected to “Control of tumour growth and functioning syndromes are the goals of the approach of advanced lung carcinoids, with the objective of improving patients’ quality of life and survival.” The text originally published “Moreover, some other bi- or trispecific TCE engagers (BI-764532, HPN328, RO7616789, QLS31904, and PT217) are under evaluation for refractory DLL3-expressing NENs in several phase 1 to 2 trials, with preliminary data showing a safe toxicity profile and promising efficacy.” Has been corrected to ”Moreover, some other bi- or trispecific TCE engagers (BI-764532, HPN328, RO7616789, QLS31904, and PT217) are under evaluation for refractory DLL3-expressing NENs in several phase 1 to 2 trials, with preliminary data showing a safety toxicity profile and promising efficacy.” These errors bear no reflection on the article or its authors. The publisher apologizes to the authors and the readers for this unfortunate error.